Novel matrine derivative MD-1 attenuates hepatic fibrosis by inhibiting EGFR activation of hepatic stellate cells

Abstract

Matrine (MT), the effective component of Sophora flavescens Ait, has been shown to have anti-inflammation, immune-suppressive, anti-tumor, and anti-hepatic fibrosis activities. However, the pharmacological effects of MT still need to be strengthened due to its relatively low efficacy and short half-life. In the present study, we report a more effective thio derivative of MT, MD-1, and its inhibitory effects on the activation of hepatic stellate cells (HSCs) in both cell culture and animal models. Cytological experiments showed that MD-1 can inhibit the proliferation of HSC-T6 cells with a half-maximal inhibitory concentration (IC50) of 62 μmol/L. In addition, MD-1 more strongly inhibits the migration of HSC-T6 cells compared to MT and can more effectively induce G0/G1 arrest and apoptosis. Investigating the biological mechanisms underlying anti-hepatic fibrosis in the presence of MD-1, we found that MD-1 can bind the epidermal growth factor receptor (EGFR) on the surface of HSC-T6 cells, which can further inhibit the phosphorylation of EGFR and its downstream protein kinase B (Akt), resulting in decreased expression of cyclin D1 and eventual inhibition of the activation of HSC-T6 cells. Furthermore, in rats with dimethylnitrosamine (DMN)-induced hepatic fibrosis, MD-1 slowed the development and progression of hepatic fibrosis, protecting hepatic parenchymal cells and improving hepatic functions. Therefore, MD-1 is a potential drug for anti-hepatic fibrosis.

Keywords

matrine derivative / hepatic stellate cell / hepatic fibrosis / epidermal growth factor receptor / signal transduction pathway

References

[1] Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V (2015) Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess 19:1–409, v–vi

[2] Cuevas MJ, Tieppo J, Marroni NP, Tunon MJ, Gonzalez-Gallego J (2011) Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats. J Nutr 141:1299–1305

[3] Fagone P, Mangano K, Mammana S, Pesce A, Pesce A, Caltabiano R, Giorlandino A, Portale TR, Cavalli E, Lombardo GA (2015) Identification of novel targets for the diagnosis and treatment of liver fibrosis. Int J Mol Med 36:747–752

[4] Fausther M, Lavoie EG, Dranoff JA (2013) Contribution of myofibroblasts of different origins to liver fibrosis. Curr Pathobiol Rep 1:225–230

[5] Handy JA, Fu PP, Kumar P, Mells JE, Sharma S, Saxena NK, Anania FA (2011) Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 440:385–395

[6] Hu H, Wang S, Zhang C, Wang L, Ding L, Zhang J, Wu Q (2010) Synthesis and in vitro inhibitory activity ofmatrine derivatives towards pro-inflammatory cytokines. Bioorg Med Chem Lett 20:7537–7539

[7] Iimuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, Brenner DA, Yamaoka Y (2003) Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124:445–458

[8] Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH (2014a) Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA 111:E3297–E3305

[9] Iwaisako K, Taura K, Koyama Y, Takemoto K, Asagiri M (2014b) Strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies. Curr Pathobiol Rep 2:209–215

[10] Jang YO, Jun BG, Baik SK, Kim MY, Kwon SO (2015) Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol 21:141–149

[11] Koo JH, Lee HJ, Kim W, Kim SG (2016) Endoplasmic reticulum stress in hepatic stellate cells promotes liver fibrosis via PERKmediated degradation of HNRNPA1 and up-regulation of SMAD2. Gastroenterology 150(181–193):e188

[12] Liu Y, Liu H, Meyer C, Li J, Nadalin S, Konigsrainer A, Weng H, Dooley S, ten Dijke P (2013) Transforming growth factor-beta (TGF-beta)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem 288:30708–30719

[13] Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q, Su C (2014) Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 35:5111–5119

[14] Page A, Paoli PP, Hill SJ, Howarth R, Wu R, Kweon SM, French J, White S, Tsukamoto H, Mann DA (2015) Alcohol directly stimulates epigenetic modifications in hepatic stellate cells. J Hepatol 62:388–397

[15] Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E (2015) Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients. Ann Gastroenterol 28:374–378

[16] Pinzani M (2015) Pathophysiology of liver fibrosis. Dig Dis 33:492–497

[17] Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, Okita K (2004) Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40:1304–1311

[18] Seki E, Brenner DA (2015) Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci 22:512–518

[19] Shimada H, Staten NR, Rajagopalan LE (2011) TGF-beta1 mediated activation of Rho kinase induces TGF-beta2 and endothelin-1 expression in human hepatic stellate cells. J Hepatol 54:521–528

[20] Tang WP, Akahoshi T, Piao JS, Narahara S, Murata M, Kawano T, Hamano N, Ikeda T, Hashizume M (2015) Basic fibroblast growth factor-treated adipose tissue-derived mesenchymal stem cell infusion to ameliorate liver cirrhosis via paracrine hepatocyte growth factor. J Gastroenterol Hepatol 30:1065–1074

[21] Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383:1749–1761

[22] Voon DC, Wang H, Koo JK, Chai JH, Hor YT, Tan TZ, Chu YS, Mori S, Ito Y (2013) EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One 8:e70427

[23] Wallace MC, Friedman SL (2014) Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. Gene Expr 16:77–84

[24] Wang FP, Li L, Li J, Wang JY, Wang LY, Jiang W (2013) High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS One 8:e64373

[25] Xu WH, Hu HG, Tian Y, Wang SZ, Li J, Li JZ, Deng X, Qian H, Qiu L, Hu ZL (2014) Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis. Hepatology 60:648–660

[26] Xu Y, Peng Z, Ji W, Li X, Lin X, Qian L, Li X, Chai X, Wu Q, Gao Q (2015) A novel matrine derivative WM130 inhibits activation of hepatic stellate cells and attenuates dimethylnitrosamineinduced liver fibrosis in rats. Biomed Res Int 2015:203978

[27] Zhang B, Liu ZY, Li YY, Luo Y, Liu ML, Dong HY, Wang YX, Liu Y, Zhao PT, Jin FG (2011) Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci 44:573–579

[28] Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, Guo C (2001) Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin 22:183–186

RIGHTS & PERMISSIONS

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn